Southern California Research Center | Coronado, CA

Research site

(Unclaimed)

Location

131 Orange Avenue, Suite 101, Coronado, California, United States of America

Site insights

Top conditions

Top treatments

EDP-305

Ribavirin

Elafibranor

MK-7240

Semaglutide

BMS-650032

Prednisolone

Daclatasvir

Volixibat

Golimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 74 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).PBC is a slowly progressiv...

Enrolling

Primary Biliary Cholangitis (PBC)

Drug: Elafibranor

Other: Matched 80 mg placebo

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic...

Enrolling

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

Locations recently updated

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting

Colitis, Ulcerative

Biological: JNJ-78934804

Drug: Placebo

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE)

The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication...

Enrolling

Primary Biliary Cholangitis

Other: Placebo

Drug: Elafibranor

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severe...

Enrolling

Ulcerative Colitis Chronic

Ulcerative Colitis

Drug: Placebo

Drug: Eltrekibart

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Nofazinlimab (CS1003)+Lenvatinib

Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

PBC

Primary Biliary Cholangitis

Drug: Placebo

Drug: Volixibat

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

Primary Sclerosing Cholangitis

Drug: Placebo

Drug: Volixibat

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Enrolling

Ulcerative Colitis

Drug: IV Placebo

Drug: SC Placebo

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling

Crohn's Disease

Other: SC Placebo

Drug: IV Tulisokibart

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with...

Enrolling

Compensated Cirrhosis

Primary Biliary Cholangitis

Drug: K-808

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Compensated Liver Cirrhosis

Drug: BI 770371

Drug: Placebo for BI 770371

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

VAY736 dose testing; VAY736 efficacy and safety testing.

Active, not recruiting

Autoimmune Hepatitis

Other: Placebo

Biological: VAY736

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Drug: Placebo matching survodutide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Drug: Survodutide

Drug: Placebo

Safety and Tolerability of NTR-101 in Patients with Acute Alcohol-Associated Hepatitis (PhoenixAH)

The goal of this clinical trial is to learn about the safety and tolerability of NTR-101 in adult participants suffering from acute alcohol-associate...

Not yet enrolling

Alcohol-Associated Hepatitis

Drug: bacteriophage preparation

Drug: Bacteriophage preparation

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2...

Enrolling

Cirrhosis, Liver

Liver Fibrosis

Drug: PHIN-214 Subcutaneous injection

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling

Ulcerative Colitis

Drug: Tilpisertib Fosmecarbil

Drug: Placebo